🇺🇸 FDA
Pipeline program

Brelovitug 300 mg

BJT-778-301

Phase 3 small_molecule active

Quick answer

Brelovitug 300 mg for Chronic Hepatitis D Infection is a Phase 3 program (small_molecule) at Mirum Pharmaceuticals with 3 ClinicalTrials.gov record(s).

Program details

Company
Mirum Pharmaceuticals
Indication
Chronic Hepatitis D Infection
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials